The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Intercept Pharmaceuticals Inc

Nasdaq: ICPT
Last

(U.S.) $150.45

Today's change+1.25 +0.84%
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.
 

Intercept Pharmaceuticals Inc

Nasdaq: ICPT
Last

(U.S.) $150.45

Today's change+1.25 +0.84%
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.

Intercept Pharmaceuticals Inc up (U.S.)$1.25

Intercept Pharmaceuticals Inc closed up Wednesday by (U.S.)$1.25 or 0.84% to (U.S.)$150.45. Shares have lost 3.51% over the last five days, but have gained 120.34% over the last year to date. This security has outperformed the S&P 500 by 174.85% during the last year.

Key company metrics

  • Open(U.S.) $148.74
  • Previous close(U.S.) $149.20
  • High(U.S.) $152.01
  • Low(U.S.) $147.51
  • Bid / Ask-- / --
  • YTD % change+120.34%
  • Volume285,703
  • Average volume (10-day)498,588
  • Average volume (1-month)680,180
  • Average volume (3-month)484,014
  • 52-week range(U.S.) $50.90 to (U.S.) $497.00
  • Beta--
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEG2.57×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$12.76
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue0000
Total other revenue--------
Total revenue0000
Gross profit--------
Total cost of revenue--------
Total operating expense37232014
Selling / general / administrative9865
Research & development27151410
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-36-22-20-14
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-3633-246-12
Income after tax-3633-246-12
Income tax, total--000
Net income-3633-246-12
Total adjustments to net income------0
Net income before extra. items-3633-246-12
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-3633-246-12
Inc. avail. to common incl. extra. items-3633-246-12
Diluted net income-3633-246-12
Dilution adjustment------0
Diluted weighted average shares21222119
Diluted EPS excluding extraordinary itemsvalue per share-1.691.51-11.94-0.64
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-1.691.51-11.94-0.64